Quarterly Result8 May 2026, 10:11 pm
Bajaj Healthcare FY26 Revenue Up 12.6%, PAT Up 27.1%
AI Summary
Bajaj Healthcare Ltd announced its FY26 results, reporting a 12.6% increase in revenue and a 27.1% rise in Profit After Tax (PAT) from continuing operations. API exports grew by 51.6%, and the formulations business also saw a 12.6% increase. The company filed 41 DMFs in Q4, bringing the total to 110. Cenobamate is progressing through Phase III clinical trials, slated for launch in Q2 FY27. The company completed the conversion of warrants into equity shares, bringing in ₹527 million.
Key Highlights
- FY26 revenue increased by 12.6% YoY, driven by API exports and formulations.
- PAT from continuing operations grew by 27.1% YoY.
- API exports saw a significant growth of 51.6% YoY.
- Filed 41 DMFs in Q4, totaling 110 filings.
- Cenobamate is progressing through Phase III clinical trials.